Anixa Biosciences and MolGenie Announce Early Potency Analysis of SARS-CoV-2 Protease Inhibitor

Anixa's compound may be five times more potent than the protease inhibitor in Pfizer's PAXLOVID™ at inhibiting Mpro, the main protease of SARS-CoV-2

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.


Please enter your comment!
Please enter your name here